WALTHAM, Mass., Feb. 7 /PRNewswire/ -- Logical Therapeutics, Inc., a biotechnology company focused on the development of medicines that treat diseases associated with poorly controlled inflammation, announced today that its co-founder and CEO Mitchell P. Fink M.D. was presented with the Distinguished Investigator Award from the American College of Critical Care Medicine during the 37th Critical Care Congress of the Society of Critical Care Medicine held February 2-6 in Honolulu, Hawaii.
The prestigious recognition was awarded to Dr. Fink for his pioneering research related to the pathogenesis and treatment of sepsis, a serious medical condition characterized by widespread inflammation, due to infection.
Dr. Fink was the Founding Chairman of the Department of Critical Care Medicine at the University of Pittsburgh, the first such department at a medical school in the United States. Dr Fink also held other University appointments including Professor of Pharmacology, the Watson Professor of Surgery, and Associate Vice-chancellor for Translational Research. Dr. Fink's academic research program was continuously funded by the National Institutes of Health for more than 20 years.
The Society of Critical Care Medicine, which bestowed the honor to Dr. Fink, is the leading professional organization dedicated to ensuring excellence and consistency in the practice of critical care medicine. With more than 13,000 members worldwide, the Society is the only professional organization devoted exclusively to the advancement of multi-professional intensive care through excellence in patient care, professional education, public education, research and advocacy.
Dr. Fink is an author or co-author of more than 250 peer-reviewed
scientific publications, has edited or co-edited 13 textbooks and is
currently an Associate Editor for two highly regarded scientific journals:
the Journal of Pharmacology and Experimental Therapeutics and the Journal
|SOURCE Logical Therapeutics, Inc.|
Copyright©2008 PR Newswire.
All rights reserved